Pelthos Therapeutics Inc. (PTHS)
PTHS moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How PTHS actually reacts to news — the realized, point-in-time move the market made, measured across 97 labeled events over the last three years with zero look-ahead.
PTHS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 61 |
| 30-min | 0.00% | 48% | 77 |
| 60-min | -0.20% | 41% | 83 |
| to close | 0.00% | 48% | 92 |
| Middle 50% of PTHS reactions | -1.43% to +1.80% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 97 |
Half of all Pelthos Therapeutics Inc. news events land between -1.43% and +1.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PTHS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTHS's baseline. Nothing else.
Recent PTHS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% | Press release | GlobeNewswire | +0.54% | +5.29% | |
| Form ARS Pelthos Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.53% | -2.90% | |
| Form DEF 14A Pelthos Therapeutics For: Sep 29 | SEC filing · Form DEF | SEC EDGAR | +0.53% | -2.90% | |
| Form DEFA14A Pelthos Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.53% | -2.90% | |
| Form 10-Q Pelthos Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.83% | +4.14% | |
| Form 10-Q/A Pelthos Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.83% | +4.14% | |
| Form 8-K Pelthos Therapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +5.83% | +4.14% | |
| Form 8-K Pelthos Therapeutics For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +5.83% | +4.14% | |
| Pelthos Therapeutics Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +5.83% | +4.14% | |
| Form PRE 14A Pelthos Therapeutics For: Sep 29 | SEC filing · Form PRE | SEC EDGAR | — | — | |
| Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 | Press release | GlobeNewswire | +0.00% | -6.35% | |
| Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders | Press release | GlobeNewswire | +0.91% | +0.84% | |
| Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes | Press release | GlobeNewswire | — | +0.04% | |
| Form 8-K Pelthos Therapeutics For: May 28 | SEC filing · Form 8-K | SEC EDGAR | — | +1.46% | |
| Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | — | +1.46% | |
| Form 8-K Pelthos Therapeutics For: May 15 | SEC filing · Form 8-K | SEC EDGAR | — | -1.55% | |
| Form 10-Q Pelthos Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.85% | +2.56% | |
| Form 8-K Pelthos Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.85% | +2.56% | |
| Pelthos Therapeutics Announces First Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.85% | +2.56% | |
| Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | GlobeNewswire | — | -0.28% | |
| Form 8-K Pelthos Therapeutics For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.96% | |
| Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium | Press release | GlobeNewswire | +0.00% | -1.96% | |
| Form 8-K Pelthos Therapeutics For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | — | +2.77% | |
| Pelthos Therapeutics Announces CFO Transition | Press release | GlobeNewswire | — | +2.77% | |
| Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain | Press release | GlobeNewswire | — | -0.80% | |
| Form 10-K Pelthos Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -7.95% | |
| Form 8-K Pelthos Therapeutics For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.95% | |
| Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -7.95% | |
| Pelthos Therapeutics to Present at 38th Annual ROTH Conference | Press release | GlobeNewswire | — | — | |
| Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 | Press release | GlobeNewswire | — | +0.22% | |
| Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.00% | +3.53% | |
| Form EFFECT Pelthos Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -2.23% | +2.34% | |
| Form S-3 Pelthos Therapeutics | SEC filing · Form S-3 | SEC EDGAR | — | -6.97% | |
| Form 8-K Pelthos Therapeutics For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | — | -3.17% | |
| Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance | Press release | GlobeNewswire | — | -3.17% | |
| Form 8-K Pelthos Therapeutics For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | — | -3.17% | |
| Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice | Press release | GlobeNewswire | -6.97% | -2.26% | |
| Form 8-K Pelthos Therapeutics For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | -6.97% | -2.26% | |
| Form 8-K Pelthos Therapeutics For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.20% | |
| Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn | Press release | GlobeNewswire | +0.00% | +2.20% | |
| Form 8-K Pelthos Therapeutics For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | — | +2.90% | |
| Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% | Press release | GlobeNewswire | +10.02% | +3.98% | |
| Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.00% | -5.74% | |
| Form ARS Pelthos Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -5.74% | |
| Form DEF 14A Pelthos Therapeutics For: Dec 17 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.69% | |
| Form D Pelthos Therapeutics | SEC filing · Form D | SEC EDGAR | — | -5.42% | |
| Form PRE 14A Pelthos Therapeutics For: Nov 14 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.76% | |
| Form 10-Q Pelthos Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K Pelthos Therapeutics For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results | Press release | GlobeNewswire | +0.00% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTHS section they belong to.
Where else PTHS is measured.
PTHS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pelthos Therapeutics Inc.'s median reaction calculated?
Every labeled PTHS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 97 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of PTHS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTHS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.